Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor

PURPOSE: Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and a model of targeted molecular therapy. GIST depends on oncogenic KIT signaling and responds to the tyrosine kinase inhibitor imatinib. However, imatinib is rarely curative. We hypothesized that PLX3397, which inhibit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, Teresa S., Cavnar, Michael J., Cohen, Noah A., Sorenson, Eric C., Greer, Jonathan B., Seifert, Adrian M., Crawley, Megan H., Green, Benjamin L., Popow, Rachel, Pillarsetty, Nagavarakishore, Veach, Darren R., Ku, Anson T., Rossi, Ferdinand, Besmer, Peter, Antonescu, Cristina R., Zeng, Shan, DeMatteo, Ronald P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4008656/
https://ncbi.nlm.nih.gov/pubmed/24583793
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-3033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados